https://mindmedicinelaw.com/briefing/dea-maintains-schedule-i-status-for-mgm-15-and-mgm-16-in-the-us-20261014-49838The Psychedelic Journalen2026-10-14T15:05:23.333983+00:00DEA Maintains Schedule I Status for MGM-15 and MGM-16 in the USdea scheduling, mgm-15, mgm-16, kratom analogs, schedule i controlled substances, federal register, research barriers, controlled substances act, regulatory policy, mitragynine analogshttps://mindmedicinelaw.com/briefing/dea-temporarily-schedules-key-kratom-alkaloids-above-threshold-20261014-49837The Psychedelic Journalen2026-10-14T15:05:02.982651+00:00DEA Temporarily Schedules Key Kratom Alkaloids Above Thresholddea scheduling, kratom alkaloids, 7-hydroxymitragynine, mitragynine pseudoindoxyl, controlled substances act, threshold scheduling, research barriers, market impact, federal policy, psychoactive regulationhttps://mindmedicinelaw.com/briefing/rtms-response-varies-by-depressive-phenotype-preclinical-insights-20261013-50094The Psychedelic Journalen2026-10-14T22:07:25.644610+00:00rTMS Response Varies by Depressive Phenotype: Preclinical InsightsrTMS, treatment-resistant depression, phenotype-specific response, neuroendocrine markers, Bdnf, Cnr1, preclinical depression models, personalized neuromodulation, psychedelic research, biomarker-guided trialshttps://mindmedicinelaw.com/briefing/psychedelic-induced-personality-changes-evidence-and-gaps-global-2014-2024-20261013-50054The Psychedelic Journalen2026-10-14T22:06:37.426471+00:00Psychedelic-Induced Personality Changes: Evidence and Gaps (Global, 2014–2024)psychedelic research, personality trait change, neuroticism, systematic review, clinical trial design, regulatory considerations, mental health, psilocybin, LSD, ayahuascahttps://mindmedicinelaw.com/briefing/ketamine-for-trd-efficacy-differs-by-depression-subtype-and-trauma-20261013-50095The Psychedelic Journalen2026-10-14T22:06:15.711177+00:00Ketamine for TRD: Efficacy Differs by Depression Subtype and Traumaketamine, treatment-resistant depression, melancholic depression, depressive subtypes, childhood trauma, psychedelic-assisted therapy, clinical trials, precision psychiatry, biomedical ketamine, regulatory policyhttps://mindmedicinelaw.com/briefing/multimodal-imaging-validates-plasticity-markers-after-dmt-ketamine-in-uk-study-20261013-50112The Psychedelic Journalen2026-10-14T22:05:56.426871+00:00Multimodal Imaging Validates Plasticity Markers After DMT, Ketamine in UK Studysynaptic plasticity, pet imaging, dmt, ketamine, neuroimaging biomarkers, clinical trial endpoints, sv2a, diffusion weighted imaging, eeg, psychedelic researchhttps://mindmedicinelaw.com/briefing/pharmacist-training-for-psychedelic-medicine-u-s-readiness-grows-20261013-49829The Psychedelic Journalen2026-10-13T22:04:01.630882+00:00Pharmacist Training for Psychedelic Medicine: U.S. Readiness Growspharmacist training, psychedelic medicine, mdma, psilocybin, fda approval, pharmacy education, controlled substances, public health, regulatory readiness, patient safetyhttps://mindmedicinelaw.com/briefing/psychedelic-medicine-after-fda-approval-us-policy-and-market-readiness-20261013-49653The Psychedelic Journalen2026-10-13T15:06:13.305711+00:00Psychedelic Medicine After FDA Approval: US Policy and Market Readinesspsychedelic medicine, fda approval, us policy, dea scheduling, vicente llp, clinical operations, investor considerations, state law, remediation strategies, risk managementhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-safety-audit-regulatory-success-cost-barriers-remain-20261013-49654The Psychedelic Journalen2026-10-13T15:05:58.965101+00:00Oregon’s Psilocybin Safety Audit: Regulatory Success, Cost Barriers Remainoregon psilocybin law, psilocybin safety audit, psychedelic regulation, access barriers, public health policy, measure 109, equity in psychedelics, psychedelic industry costs, facilitator training, regulatory compliancehttps://mindmedicinelaw.com/briefing/acute-basolateral-amygdala-dbs-shows-no-behavioral-impact-in-rats-20261012-50098The Psychedelic Journalen2026-10-14T22:09:19.779757+00:00Acute Basolateral Amygdala DBS Shows No Behavioral Impact in Ratsdeep brain stimulation, basolateral amygdala, preclinical safety, psychiatric neuromodulation, anxiety behavior, fear memory, rat models, translational research, psychedelic research, regulatory sciencehttps://mindmedicinelaw.com/briefing/oral-ketamine-assisted-psychotherapy-in-dnsd-case-report-and-clinical-implicatio-20261012-50100The Psychedelic Journalen2026-10-14T22:08:54.295379+00:00Oral Ketamine-Assisted Psychotherapy in DNSD: Case Report and Clinical Implicationsketamine-assisted psychotherapy, dissociative neurological symptom disorder, functional neurological disorder, case report, oral ketamine, mutism, treatment-resistant, psychedelic research, clinical evidence, off-label usehttps://mindmedicinelaw.com/briefing/psychedelic-assisted-therapy-in-ukraine-evidence-gaps-and-future-directions-20261012-50057The Psychedelic Journalen2026-10-14T22:08:36.319782+00:00Psychedelic-Assisted Therapy in Ukraine: Evidence, Gaps, and Future Directionspsychedelic-assisted therapy, psilocybin, mdma, lsd, ayahuasca, ukraine, clinical trials, mental health, policy, evidence gapshttps://mindmedicinelaw.com/briefing/standardizing-visual-snow-syndrome-diagnosis-implications-for-psychedelic-resear-20261012-50086The Psychedelic Journalen2026-10-14T22:08:14.259028+00:00Standardizing Visual Snow Syndrome Diagnosis: Implications for Psychedelic Researchvisual snow syndrome, diagnostic protocol, psychedelic research, adverse event monitoring, hallucinogen persisting perception disorder, cortical hyperexcitability, biomarker development, clinical trials, neurological safety, regulatory policyhttps://mindmedicinelaw.com/briefing/suzetrigine-analgesia-enhanced-by-nav1-7-null-opioid-mechanisms-preclinical-insi-20261012-50099The Psychedelic Journalen2026-10-14T22:07:51.743047+00:00Suzetrigine Analgesia Enhanced by Nav1.7 Null Opioid Mechanisms: Preclinical Insightssuzetrigine, nav1.7 sodium channel, endogenous opioid signaling, analgesia, pain management, preclinical research, rgs antagonists, inflammatory pain, clinical translationhttps://mindmedicinelaw.com/briefing/low-dose-esketamine-in-emergency-c-sections-rct-evidence-from-china-20261012-50097The Psychedelic Journalen2026-10-14T22:07:02.588531+00:00Low-Dose Esketamine in Emergency C-Sections: RCT Evidence from Chinaesketamine, emergency cesarean section, labor analgesia, randomized controlled trial, maternal hemodynamics, neonatal outcomes, acute pain management, obstetric anesthesia, clinical safetyhttps://mindmedicinelaw.com/briefing/ketamine-augmentation-strategies-in-trd-meta-analysis-insights-ncbi-2026-20261012-49998The Psychedelic Journalen2026-10-14T15:05:37.897068+00:00Ketamine Augmentation Strategies in TRD: Meta-Analysis Insights (NCBI, 2026)ketamine augmentation, treatment-resistant depression, systematic review, meta-analysis, clinical protocols, psychiatric policy, IV ketamine, adverse effects, personalized psychiatry, regulatory implicationshttps://mindmedicinelaw.com/briefing/ai-s-expanding-role-in-preclinical-drug-development-implications-for-psychedelic-20261011-49589The Psychedelic Journalen2026-10-13T15:06:45.573805+00:00AI’s Expanding Role in Preclinical Drug Development: Implications for Psychedelic Researchai in drug discovery, preclinical development, psychedelic compounds, generative models, toxicity prediction, regulatory guidance, experimental validation, closed-loop optimization, fda policy, medicinal chemistryhttps://mindmedicinelaw.com/briefing/bdnf-biomarkers-and-ptsd-implications-for-psychedelic-trials-20261011-49570The Psychedelic Journalen2026-10-13T15:06:29.748282+00:00BDNF Biomarkers and PTSD: Implications for Psychedelic Trialsbdnf, ptsd biomarkers, psychedelic clinical trials, neuroplasticity, epigenetics, precision psychiatry, regulatory science, biomarker panel, personalized therapyhttps://mindmedicinelaw.com/briefing/qualitative-insights-on-acute-inhaled-dmt-in-brazilian-clinics-20261007-49600The Psychedelic Journalen2026-10-13T15:06:58.990485+00:00Qualitative Insights on Acute Inhaled DMT in Brazilian Clinicsdmt, brazil, psychedelic research, qualitative study, clinical trials, subjective experience, regulatory context, ayahuasca, risk management, cultural factors